Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-adapted first-line therapy for advanced classical Hodgkin lymphoma
ACTRN12608000639325Phase 2Recruiting
- Sponsor
- GITIL
- Start
- Jun 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide and 5 more in Hodgkin lymphoma (HL) (3 arms), sponsored by GITIL. Primary endpoint: 3-year progression-free survival. Started Jun 2008; status: recruiting.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazineetoposide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on ACTRN12608000639325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000639325.